Nautilus Biotechnology
51 articles about Nautilus Biotechnology
-
Nautilus Biotechnology Reports First Quarter 2022 Financial Results
5/3/2022
Nautilus Biotechnology, Inc., a company pioneering a single molecule proteome analysis, reported financial results for the first quarter ended March 31, 2022.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Nautilus Biotechnology Appoints Gwen Weld as Chief People Officer and Sheri Wilcox, Ph.D., as Vice President of Affinity Reagent Development
4/12/2022
Nautilus Biotechnology, Inc. announced the appointments of Gwen Weld as Chief People Officer and Sheri Wilcox, Ph.D., as Vice President of Affinity Reagent Development, adding further experience to its senior leadership team in its ongoing expansion of the organization.
-
BioSpace Movers & Shakers, April 8
4/8/2022
Onxeo, Amydis, eFFECTOR Therapeutics, Freenome, Urovant Sciences and others all added new guidance and perspectives to their C-suite this week. -
Nautilus Biotechnology to Announce First Quarter 2022 Financial Results on May 3, 2022
4/7/2022
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced it will report financial results for the first quarter 2022 before market open on Tuesday, May 3rd, 2022.
-
Nautilus Biotechnology to Present at EuPA and AACR Meetings
4/4/2022
Nautilus Biotechnology, Inc. today announced presentations at the following leading scientific and medical conferences. XIV Annual Congress of the European Proteomics Association (EuPA).
-
Nautilus Biotechnology Appoints Karen Akinsanya, Ph.D., to Board of Directors
3/31/2022
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced the appointment of Karen Akinsanya, Ph.D., to its Board of Directors.
-
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2021 Financial Results
2/24/2022
Nautilus Biotechnology, Inc., a company pioneering a single molecule proteome analysis platform, reported financial results for the fourth quarter and fiscal year ended December 31, 2021.
-
Many human diseases have been linked to malformed or malfunctioning proteins. Sickle cell disease is one example.
-
Nautilus to Participate in the 42nd Annual Cowen Health Care Conference
2/16/2022
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced the company will be participating virtually in the upcoming 42nd Annual Cowen Health Care Conference.
-
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
1/27/2022
Nautilus Biotechnology, Inc. today announced it will report financial results for the fourth quarter and full year 2021 before market open on Thursday, February 24th , 2022.
-
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
-
Many mergers took place in 2021. Here’s a look at some of the hottest life sciences SPAC merger announcements so far in 2021. Many mergers took place in 2021,
-
Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome
11/2/2021
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam, a global innovator in life sciences research tools, announced a strategic development and supply partnership.
-
Nautilus Biotechnology Reports Third Quarter 2021 Financial Results
11/2/2021
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, reported financial results for the third quarter ended September 30, 2021.
-
Wanting to find out what is fueling the trend, BioSpace solicited the perspectives of a couple of executives who chose the SPAC route.
-
Jose Luis Casero Sanchez took advantage of his position in Goldman Sachs’ “control room” to gain insider knowledge of upcoming transactions, including those for several biopharma companies.
-
With the adaptation of new technologies, tech executives are finding new homes in biotech and the life sciences.
-
Nautilus to Participate in the Morgan Stanley Global Healthcare Conference
9/3/2021
Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, today announced the company will be participating virtually in the upcoming Morgan Stanley Global Healthcare Conference.
-
BioSpace Movers & Shakers, Aug. 13
8/13/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.